PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets… Read more
PlexBio Co., Ltd. (6572) - Total Liabilities
Latest total liabilities as of June 2025: NT$196.72 Million TWD
Based on the latest financial reports, PlexBio Co., Ltd. (6572) has total liabilities worth NT$196.72 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PlexBio Co., Ltd. - Total Liabilities Trend (2020–2024)
This chart illustrates how PlexBio Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PlexBio Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of PlexBio Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HeveaBoard Bhd
KLSE:5095
|
Malaysia | RM74.42 Million |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
India | ₹1.37 Billion |
|
Beauty Skin Corp.
KQ:406820
|
Korea | ₩49.27 Billion |
|
SY PUBLIC UTIL -H- (SH3.SG)
STU:SH3
|
Germany | €207.76 Million |
|
LBT Innovations Ltd
AU:LBT
|
Australia | AU$5.51 Million |
|
Apollo Silver Corp
OTCQB:APGOF
|
USA | $307.69K |
|
Infrared Cameras Holdings Inc
NASDAQ:MSAI
|
USA | $3.59 Million |
|
Solueta Co Ltd
KQ:154040
|
Korea | ₩31.52 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down PlexBio Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PlexBio Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PlexBio Co., Ltd. (2020–2024)
The table below shows the annual total liabilities of PlexBio Co., Ltd. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$197.97 Million | +114.57% |
| 2023-12-31 | NT$92.26 Million | -10.19% |
| 2022-12-31 | NT$102.72 Million | -48.25% |
| 2021-12-31 | NT$198.48 Million | +23.48% |
| 2020-12-31 | NT$160.74 Million | -- |